SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial

Name: SUPPLEMENTARY MATERIALS: Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
Creator: Mendeley
Published: 2022-10-19T21:13:59+08:00

DataCite Commons2025-05-01 更新2025-04-16 收录

药物临床试验

皮肤病学

数据链接：

https://data.mendeley.com/datasets/vpb6m7gmhn 数据链接链接失效反馈

官方服务：

资源简介：

Supplementary materials for the publication of Armstrong A. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol 2022.

提供机构：

Mendeley

创建时间：

2022-10-19